Jade Biosciences

JBIO · NASDAQ

$14.86+$1.03 (+7.45%)TodayMarket closed · Oct 20, 5:00 PM ET

Prev close $13.83

JBIO analyst rating

BuyConsensus of 6 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy6
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $50.89 (+242.4% upside)

Low: $40.40
Now: $14.86
High: $80.85

Upgrades and downgrades

The latest rating actions, newest first

JBIO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Oct 1, 2026	Maintains	Outperform	$47.00	40%
HC Wainwright & Co.	Oct 1, 2026	Maintains	Buy	$55.00	47%
Wedbush	Aug 11, 2026	Maintains	Outperform	$45.00 → $47.00	40%
BTIG	Aug 10, 2026	Maintains	Buy	$74.00 → $77.00	34%
UBS	Jun 15, 2026	Initiates	Buy	$45.00	53%
Wedbush	Jun 2, 2026	Maintains	Outperform	$34.00 → $45.00	40%
BTIG	Jun 1, 2026	Maintains	Buy	$39.00 → $74.00	34%
HC Wainwright & Co.	Jun 1, 2026	Maintains	Buy	$45.00 → $55.00	47%
BTIG	May 27, 2026	Maintains	Buy	$39.00	34%
Guggenheim	May 11, 2026	Maintains	Buy	$23.00 → $32.00	66%

The case for and against

Updated Oct 14, 2026

Bull case

Jade Biosciences is viewed positively because its lead asset JADE101 is being de-risked by external APRIL-inhibition data showing kidney-function stabilization in IgAN, while JADE101 is believed to offer greater potency and longer dosing intervals than Voyxact, supporting differentiation in an early market. The company also appears to have meaningful pipeline optionality: JADE301 showed roughly 2.5-fold higher IFN-β affinity versus the dazukibart comparator, 2.5-fold better potency in immune cells, and about 8-fold better suppression in dermal fibroblasts, with a clean GLP toxicology profile in NHPs and a planned 4Q26 Phase 1 study. Financially, the view is further supported by a reported higher net cash position after $29M in ATM activity, while upcoming catalysts in 4Q26, 2H27, and 2027 could validate both programs.

Bear case

Jade Biosciences is a clinical-stage biotech whose investment case remains fundamentally weak because JADE101 is still only in a Phase 1 trial for IgAN, while JADE201 and JADE301 remain earlier-stage assets with no approved products or revenue base. Its valuation is heavily dependent on optimistic assumptions, including a 40% probability of launch for IgAN, 25% peak penetration, a 10% discount rate, and a 3% terminal growth rate, underscoring how sensitive the story is to clinical success that has yet to be demonstrated. The company’s reported $461M in net cash helps fund development, but the stated need for additional external financing raises dilution risk, while regulatory uncertainty, competition, and the possibility of longer or additional studies all threaten timelines and capital efficiency.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.